EGFR and neoplasm: More importantly, ex vivo gene editing therapy is unlikely to be used for molecules expressed by tumor cells, especially solid tumor cells; instead, these molecular targets, such as PD‐L1 and EGFR, and in the case of GDF15 used in this study, are much more numerous and of greater significance in tumor therapy.